-transparent.png){kind=logo}
Effects of nefiracetam, DM-9384 on amnesia and decrease in choline acetyltransferase activity induced by cycloheximide. 1992
T Shiotani, and
K Tohyama, and
K Murase, and
S Ishihara, and
T Kameyama, and
T Yamasaki, and
S Hatanaka, and
H Kojima, and
Y Takasu, and
T Nabeshima
Tokyo Research and Development Center, Daiichi Pharmaceutical Co. Ltd., Japan.
The effects of nefiracetam, [N-(2,6-dimethyl-phenyl)-2-(2-oxo-pyrrolidinyl)acetamide, DM-9384], a cyclic derivative of GABA, were investigated in the cycloheximide (CXM)-induced amnesia animal model using the passive avoidance task. Pre-training administration of DM-9384 attenuated the CXM-induced amnesia as indicated by prolongation of step-down latency. It protected against CXM-induced inhibition of choline acetyltransferase activity in the cerebral cortex. These results suggest that DM-9384 attenuates CXM-induced amnesia by interacting with AChergic neuronal system and enhancing protein synthesis in the brain.
Related Publications
T Shiotani, and
K Tohyama, and
K Murase, and
S Ishihara, and
T Kameyama, and
T Yamasaki, and
S Hatanaka, and
H Kojima, and
Y Takasu, and
T Nabeshima
April 1991,
The Journal of pharmacology and experimental therapeutics,
T Shiotani, and
K Tohyama, and
K Murase, and
S Ishihara, and
T Kameyama, and
T Yamasaki, and
S Hatanaka, and
H Kojima, and
Y Takasu, and
T Nabeshima
June 1992,
European journal of pharmacology,
T Shiotani, and
K Tohyama, and
K Murase, and
S Ishihara, and
T Kameyama, and
T Yamasaki, and
S Hatanaka, and
H Kojima, and
Y Takasu, and
T Nabeshima
June 1996,
Neurochemical research,
T Shiotani, and
K Tohyama, and
K Murase, and
S Ishihara, and
T Kameyama, and
T Yamasaki, and
S Hatanaka, and
H Kojima, and
Y Takasu, and
T Nabeshima
January 1994,
Archives internationales de pharmacodynamie et de therapie,
T Shiotani, and
K Tohyama, and
K Murase, and
S Ishihara, and
T Kameyama, and
T Yamasaki, and
S Hatanaka, and
H Kojima, and
Y Takasu, and
T Nabeshima
March 1994,
Psychopharmacology,
T Shiotani, and
K Tohyama, and
K Murase, and
S Ishihara, and
T Kameyama, and
T Yamasaki, and
S Hatanaka, and
H Kojima, and
Y Takasu, and
T Nabeshima
June 1990,
Pharmacology, biochemistry, and behavior,
T Shiotani, and
K Tohyama, and
K Murase, and
S Ishihara, and
T Kameyama, and
T Yamasaki, and
S Hatanaka, and
H Kojima, and
Y Takasu, and
T Nabeshima
February 1997,
Behavioural brain research,
T Shiotani, and
K Tohyama, and
K Murase, and
S Ishihara, and
T Kameyama, and
T Yamasaki, and
S Hatanaka, and
H Kojima, and
Y Takasu, and
T Nabeshima
November 1993,
Brain research,
T Shiotani, and
K Tohyama, and
K Murase, and
S Ishihara, and
T Kameyama, and
T Yamasaki, and
S Hatanaka, and
H Kojima, and
Y Takasu, and
T Nabeshima
March 1990,
European journal of pharmacology,
T Shiotani, and
K Tohyama, and
K Murase, and
S Ishihara, and
T Kameyama, and
T Yamasaki, and
S Hatanaka, and
H Kojima, and
Y Takasu, and
T Nabeshima
April 1994,
Brain research,
